Altre lingue Gilead Sciences, Inc. Sao Paulo

Azioni

Tempo differito Sao Paulo Altri mercati azionari 16:25:55 27/06/2024			Variaz. 5gg	Var. 1 gen.
191,5 ^BRL	+11,39%		+2,65%	-0,54%

05:00	Gilead Sciences, Inc. annuncia nuovi dati a sostegno dell'uso del regime BICtegravir in compresse per il trattamento di persone con HIV e individui con infezione da HIV/HBV in Asia	CI
25/06	IDEAYA Biosciences annuncia l'ingresso del primo paziente nello studio clinico di Fase 1 che valuta la combinazione di IDE397 e Trodelvy nel tumore della vescica con delezione MTAP	CI

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	05:00
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	25/06
MÄRKTE USA/Knapp behauptet am Hexensabbat	21/06
MÄRKTE USA/Wall Street stabilisiert sich	21/06
Gilead small molecule demonstrates strong capability for HIV prevention	21/06
MÄRKTE USA/Wall Street startet vor Daten verhalten	21/06
Tech overload on Wall Street	21/06
Wall Street set for muted open as investors await business survey data	21/06
MÄRKTE USA/Wall Street vor verhaltenem Beginn	21/06
Nvidia Slide Stifles US Equity Futures Pre-Bell	21/06
Top Premarket Gainers	21/06
Wall Street futures edge lower ahead of business survey data	21/06
Valores destacados al cierre del mercado norteamericano	21/06
Gilead Sciences : Access Planning in High Incidence, Resource Limited Countries for Lenacapavir for HIV Prevention	21/06
Equity Markets Close Mixed as Investors Weigh Economic Data	20/06
Equity Markets Close Mixed After Macro Data	20/06
L'action de la biotech Gilead bondit après des résultats prometteurs liés au VIH	20/06
Health Care Stocks Rise Behind Gilead -- Health Care Roundup	20/06
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data	20/06
Sector Update: Health Care Stocks Higher Late Afternoon	20/06

Non ci sono risultati per questa ricerca